Comparison of 60 or 90 mg/m2 of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|2|E29-E30

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.2, 2015-02, pp. : E29-E30

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 639-646

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate‐risk karyotype in first complete remission

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 5, 2015-05 ,pp. : 431-438

John Wiley & Sons Inc

Access to resources Recommend Favorite

Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high‐risk myelodysplastic syndrome

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 6, 2015-06 ,pp. : 483-486

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 401-407

John Wiley & Sons Inc

Access to resources Recommend Favorite

“Epigenetic” modification as therapy for acute myeloid leukemia

By  

CANCER, Vol. 124, Iss. 2, 2018-01 ,pp. : 242-244

John Wiley & Sons Inc

Access to resources Recommend Favorite